Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001683168-25-008466
Filing Date
2025-11-14
Accepted
2025-11-14 17:10:42
Documents
42
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q FOR SEP 2025 cns_i10q-093025.htm   iXBRL 10-Q 475064
2 CERTIFICATION cns_ex3101.htm EX-31.1 6812
3 CERTIFICATION cns_ex3102.htm EX-31.2 6858
4 CERTIFICATION cns_ex3201.htm EX-32.1 3023
5 CERTIFICATION cns_ex3202.htm EX-32.2 3361
  Complete submission text file 0001683168-25-008466.txt   2902252

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE cnsp-20250930.xsd EX-101.SCH 20949
7 XBRL CALCULATION FILE cnsp-20250930_cal.xml EX-101.CAL 27049
8 XBRL DEFINITION FILE cnsp-20250930_def.xml EX-101.DEF 106355
9 XBRL LABEL FILE cnsp-20250930_lab.xml EX-101.LAB 254698
10 XBRL PRESENTATION FILE cnsp-20250930_pre.xml EX-101.PRE 209361
44 EXTRACTED XBRL INSTANCE DOCUMENT cns_i10q-093025_htm.xml XML 283024
Mailing Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027
Business Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027 1-800-946-9185
CNS Pharmaceuticals, Inc. (Filer) CIK: 0001729427 (see all company filings)

EIN.: 822318545 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39126 | Film No.: 251488111
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)